Published January 1, 2016 | Version v1
Journal article Open

Inhibition of human DNA topoisomerase II alpha by two novel ellipticine derivatives

  • 1. Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
  • 2. Dokuz Eylul Univ, Fac Sci, Dept Chem, TR-35160 Izmir, Turkey
  • 3. Pamukkale Univ, Fac Med, Dept Med Biol, TR-20070 Denizli, Turkey
  • 4. Ege Univ, Fac Pharm, Dept Pharmaceut Biotechnol, TR-35100 Izmir, Turkey

Description

Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity. Unfortunately, this compound displays a number of adverse properties. Therefore, to investigate new ellipticine-based compounds for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivatives, N-methyl-5-demethyl ellipticine (ET1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2). As determined by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase II alpha and are both more potent than the parent compound. Neither compound impairs the ability of the type II enzyme to bind its DNA substrate. Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase II alpha appears to be related to their ability to intercalate into the double helix. (C) 2016 Elsevier Ltd. All rights reserved.

Files

bib-d61e96c7-531b-4e6b-923b-6357800dae7f.txt

Files (224 Bytes)

Name Size Download all
md5:cf2ad6b9dd676400eaea30f14a48c345
224 Bytes Preview Download